U.S. Patient and Trademark Office, U.S. DEPARTME Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid

	Application Humber		103/1034	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Filing Date		2006-04-26	
	First Named Inventor Dietro		nar KRAUTWURST	
	Art Unit			
	Examiner Name			
	Attorney Docket Numb	er	102790-211/30246US	

U.S.PATENTS Remove						Remove					
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Line ant Passages es Appear		
	1	6492143	B1	2002-10	3-12	Reed et al.					
If you wis	h to a	dd additional U.S. Pater	t citatio	n inform	ation pl	ease click the	Add button.		Add		
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Relev	s,Columns,Line ant Passages es Appear		
	1										
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	lease click the Ad	d buttor	n. Add		\neg
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code4	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Colum where Releva Passages or F Figures Appea	nt Relevant	T5
	1	02/006311	wo		A2	2002-01-24	Merck Patent Gmb	н			
	2	2147402	AU				-				
	3	1235859	EP		A						П

	4	02/059274	wo	A2	2002-08-01	Vanderbilt University		
	5	02/38605	wo	A1	2002-05-16	Shanghai Biowindow Gene Development Inc.		
	6	01/036484	wo	A1	2001-05-25	Merck Patent GmbH		
	7	1376691	CN		2002-10-30	Biowindow Gene Development Inc.		
	8	1376713	CN		2002-10-30	Biowindow Gene Development Inc.		
	9	1380323	CN		2002-11-20	Shanghai Biowindow Gene Development Inc.		
	10	1386760	CN		2002-12-25	Biowindow Gene Development Inc.		
	11	03/004611	wo	A2	2003-01-16	Senomyx, Inc.	Cited in the application; paragraph '0003l; figure 9, examples 1, 3; page 2, line 10 line 20	
	12	01/51609	wo	A1	2001-07-07	The Johns Hopkins University		
If you wish	h to ac	dd additional Foreign Pa	atent Document	citation	information pl	ease click the Add buttor	Add	
NON-PATENT LITERATURE DOCUMENTS Remove								
Examiner Cite Initials* No (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s),							T5	

publisher, city and/or country where published.

Application Number 1057/094 Fing Date 2006-04-26 Fi

1	Copy of International Search Report dated January 31, 2005 for application PCT/EP2004/012096	
2	ILLING NICOLA ET AL.: "Conditionally immortalized closel cell lines from the mouse cifactory pisacode differentiate into clitactory recept ceres." MCLECULAR AND CELLULAR NEUROSCIENCE, vol. 20, no. 2, June 2002 (2002-06), pages 225-243, PROSCIPTOS), SSN: 1044-745; labblastic	
3	SHIGKOVIA E. ET Al.: "identification of specific ligands for orphan ollustory receptors. G-protein dependent agenism and antagons of observations of observations of protein dependent (2004):2-14), XP022315764, Rethered from the Internet URL http://levvib.pc.org/op/internitMN105020017-interinved on 2005-01-26F, Published online altead of print December 14, 2004, J. Biol. Chem, 10.1074/jbc. MN11502000 page 3, bit-hand ookum, liste 5 me - right-hand ookum, liste 5.	
4	KAJIYA K ET AL.: "Molecular bases of odor discrimination: Reconstitution of ollactory receptors that recognize overlapping sets of odorants." The JOURNAL OF PIKE RECOGNIZED. THE SOCIETY FOR NELIROSCIENCE: 15 AUG 2001, vol. 21, no. 16, 15 August 2001 (2001-00-15), pages 6018-6025, XVD0231970). SSSN: 1262-2401; order in the applications, the whole document of	
5	VILSON SET AL. "DEPHAN CAPOTEM-COUPLED RECEPTORS. THE NEXT GENERATION OF DRUG TARGETS?" BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 125, no. 7, December 1896 (1998-12), pages 1987-1996, PP01910508, ISSN: 0007-1185, dark in the application; the whole document	
6	REED R.R. "Signaling pathways in odorant detection." NEURON, FEB 1982, vol. 8, no. 2, February 1992 (1992-02), page 205-209, XP002315707; ISSN: 0896-6273; figure 1	
7	BRIZZONE R ET AL. "CONNECTIONS WITH CONNEXINS: THE MOLECULAR BASIS OF DIRECT INTERCELLILAR SIGNAL INC"; EUROPEAN JOURNAL OF BIOCHEMISTRY, BERLIN, DE, vol. 238, 1996, pages 1-27, XP002913266, ISSN: 0014-2566, the whole document	
8	English language abstract of CN 1386760	
9	English language abstract of CN 1380323	
10	English language abstract of CN 1376713	
11	English language abstract of CN 1376691	

	Application Number		10577094	
NEODIATION DIOCI COURT	Filing Date		2006-04-26	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor	Dietn	nar KRAUTWURST	
(Not for submission under 37 CFR 1.99)	Art Unit			
	Examiner Name			
	Attorney Docket Numb	er	102790-211/30246US	

 		_	
12	For AU2147402, an English language abstract for corresponding patent application WO 02/38605		

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04, 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 If possible, *Applicant is to place a check mark here if English language translation is attached.

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) Application Number | 10577094 | Filing Date | 2006-04-26 | Filing Date | 2006-04-26 | Art Unit | Examiner Name | Examine

Attorney Docket Number 1

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):	
---	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e/t1).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a final representation of an accurate part foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. Sex 7 CFR 1.97(c)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Andrew N. Parfomak/	Date (YYYY-MM-DD)	2006-05-19
Name/Print	Andrew N. Parfornak	Registration Number	32431

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually the principal purpose and for examines your submission, which may visually intermediate or of extended now about the principal purpose.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuint to 5 U.S.C. 552a(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs and of that agency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.